Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future (Q36097233)

12 August 2017

1 reference

title

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future (English)

1 reference

12 August 2017

Vassilios I Avramis

1

1 reference

12 August 2017

Eduard H Panosyan

series ordinal

2

1 reference

12 August 2017

1 January 2005

1 reference

Clinical Pharmacokinetics

12 August 2017

1 reference

12 August 2017

44

1 reference

12 August 2017

367-393

1 reference

12 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200544040-00003

12 August 2017

0 references

cites work

BFM group treatment results in relapsed childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Atopic hypersensitivity to L-asparaginase. Resistance to immunosuppression

1 reference

12 December 2020

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

12 December 2020

Childhood acute lymphocytic leukemia. Study VIII

1 reference

12 December 2020

Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement.

1 reference

12 December 2020

Asparaginase revisited

1 reference

12 December 2020

Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries

1 reference

12 December 2020

Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia

1 reference

12 December 2020

Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A

1 reference

12 December 2020

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

1 reference

12 December 2020

An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia

1 reference

12 December 2020

TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI

1 reference

12 December 2020

Synergistic antiviral effect of PEG-asparaginase (ONCASPAR), with protease inhibitor alone and in combination with RT inhibitors against HIV-1 infected T-cells: a model of HIV-1-induced T-cell lymphoma.

1 reference

12 December 2020

Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia

1 reference

12 December 2020

1 reference

12 December 2020

Clinical evaluation of l-asparaginase.Introduction

1 reference

12 December 2020

Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.

1 reference

12 December 2020

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia

1 reference

12 December 2020

Antilymphoma activity of L-asparaginase in vivo: clearance rates of enzyme preparations from guinea pig serum and yeast in relation to their effect on tumor growth

1 reference

12 December 2020

The incorporation of l-asparagine-14C by lymphoma 6C3HED cells: its inhibition by guinea pig serum

1 reference

12 December 2020

Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: A Report From the BFM Study Group

1 reference

12 December 2020

Two L-asparaginases from E. coli and their action against tumors

1 reference

12 December 2020

Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia

1 reference

12 December 2020

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols

1 reference

12 December 2020

Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study

1 reference

12 December 2020

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.

1 reference

12 December 2020

Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein

1 reference

12 December 2020

Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance

1 reference

12 December 2020

Nutritional effects on precursor uptake and compartmentalization of intracellular pools in relation to RNA synthesis

1 reference

12 December 2020

Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.

1 reference

12 December 2020

Evaluation of L-asparaginase: polyethylene glycol conjugate versus native L-asparaginase combined with chemotherapy. A randomized double-blind study in canine lymphoma

1 reference

12 December 2020

Asparaginases: where do we go from here?

1 reference

12 December 2020

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.

1 reference

12 December 2020

L-asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y.

1 reference

12 December 2020

Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum

1 reference

12 December 2020

Prevention and treatment of meningeal leukemia in children.

1 reference

12 December 2020

Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines

1 reference

12 December 2020

Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphocytic leukemia: a report from Childrens Cancer Study Group

1 reference

12 December 2020

Five-year follow-up of "total therapy" of childhood lymphocytic leukemia

1 reference

12 December 2020

PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.

1 reference

12 December 2020

A new L-asparaginase with antitumour activity?

1 reference

12 December 2020

Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy

1 reference

12 December 2020

Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration

1 reference

12 December 2020

Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia

1 reference

12 December 2020

A METABOLIC DIFFERENCE BETWEEN TWO LINES OF LYMPHOMA 6C3HED CELLS IN RELATION TO ASPARAGINE

1 reference

12 December 2020

Alterations in protein and nucleic acid metabolism of lymphoma 6C3HED-og cells in mice given guinea pig serum

1 reference

12 December 2020

Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

1 reference

12 December 2020

Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study

1 reference

12 December 2020

Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

1 reference

12 December 2020

Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial

1 reference

12 December 2020

Acute lymphoblastic leukemia

1 reference

12 December 2020

Pharmacokinetics and drug monitoring of L-asparaginase treatment

1 reference

12 December 2020

The evolution of cancer care for children and adults

1 reference

12 December 2020

Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.

1 reference

12 December 2020

Asparaginase and amino acids in cancer therapeutics. Cancer and Leukemia Group B Investigators

1 reference

12 December 2020

Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

1 reference

12 December 2020

Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: differences in asparagine formation and utilization in asparaginase-sensitive and

1 reference

12 December 2020

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation

1 reference

12 December 2020

Purification and Properties of Guinea Pig Serum Asparaginase*

1 reference

12 December 2020

1 reference

12 December 2020

L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans

1 reference

12 December 2020

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.

1 reference

12 December 2020

Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols

1 reference

12 December 2020

Inhibition of leukemias in man by L-asparaginase

1 reference

12 December 2020

The Children Leukemia Group: 30 years of research and achievements

1 reference

12 December 2020

Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase

1 reference

12 December 2020

Comparative pharmacokinetic studies of three asparaginase preparations

1 reference

12 December 2020

Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.

1 reference

12 December 2020

Prevention of central nervous system leukemia by irradiation

1 reference

12 December 2020

Apoptosis and the dilemma of cancer chemotherapy.

1 reference

12 December 2020

The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics.

1 reference

12 December 2020

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study

1 reference

12 December 2020

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system

1 reference

12 December 2020

Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients

1 reference

12 December 2020

Acute leukemia in children.

1 reference

12 December 2020

L-Asparaginase: discovery and development as a tumor-inhibitory agent

1 reference

12 December 2020

Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy

1 reference

12 December 2020

A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.

1 reference

12 December 2020

10.2165/00003088-200544040-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

12 August 2017

1022517387

0 references

Fatcat ID

release_2cuv2nkitna3pe3hcnxcp7323i

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2cuv2nkitna3pe3hcnxcp7323i

24 November 2022

mapped directly with Wikidata item

1 reference